Qingdao Vland Biotech INC
SSE:603739
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Qingdao Vland Biotech INC
SSE:603739
|
CN |
|
T
|
Tri Viet Asset Management Corporation JSC
VN:TVC
|
VN |
|
G
|
Gogoro Inc
NASDAQ:GGR
|
TW |
|
R
|
Rex Trueform Group Ltd
JSE:RTO
|
ZA |
|
Lycopodium Ltd
ASX:LYL
|
AU |
Balance Sheet
Balance Sheet Decomposition
Qingdao Vland Biotech INC
Qingdao Vland Biotech INC
Balance Sheet
Qingdao Vland Biotech INC
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
107
|
130
|
175
|
159
|
174
|
250
|
312
|
208
|
222
|
233
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
312
|
208
|
222
|
233
|
|
| Cash Equivalents |
107
|
130
|
175
|
159
|
174
|
250
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
183
|
98
|
170
|
212
|
292
|
199
|
|
| Total Receivables |
187
|
181
|
158
|
180
|
202
|
219
|
296
|
346
|
366
|
416
|
|
| Accounts Receivables |
162
|
154
|
135
|
147
|
167
|
191
|
252
|
304
|
330
|
370
|
|
| Other Receivables |
25
|
27
|
24
|
34
|
36
|
28
|
44
|
42
|
36
|
46
|
|
| Inventory |
71
|
78
|
87
|
99
|
106
|
125
|
157
|
174
|
205
|
189
|
|
| Other Current Assets |
23
|
18
|
18
|
22
|
41
|
51
|
36
|
30
|
39
|
32
|
|
| Total Current Assets |
389
|
407
|
439
|
461
|
706
|
742
|
972
|
969
|
1 124
|
1 069
|
|
| PP&E Net |
314
|
311
|
328
|
368
|
441
|
552
|
1 056
|
1 339
|
1 576
|
1 564
|
|
| PP&E Gross |
314
|
311
|
328
|
368
|
441
|
552
|
1 056
|
1 339
|
1 576
|
1 564
|
|
| Accumulated Depreciation |
147
|
163
|
190
|
219
|
249
|
276
|
315
|
369
|
433
|
522
|
|
| Intangible Assets |
81
|
70
|
76
|
76
|
75
|
122
|
131
|
136
|
140
|
131
|
|
| Goodwill |
10
|
10
|
10
|
10
|
10
|
10
|
20
|
20
|
84
|
84
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
14
|
|
| Long-Term Investments |
22
|
23
|
23
|
23
|
18
|
16
|
9
|
77
|
76
|
85
|
|
| Other Long-Term Assets |
6
|
7
|
8
|
8
|
31
|
9
|
33
|
37
|
29
|
34
|
|
| Other Assets |
10
|
10
|
10
|
10
|
10
|
10
|
20
|
20
|
84
|
84
|
|
| Total Assets |
822
N/A
|
828
+1%
|
884
+7%
|
945
+7%
|
1 281
+36%
|
1 452
+13%
|
2 222
+53%
|
2 579
+16%
|
3 034
+18%
|
2 981
-2%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
45
|
46
|
58
|
67
|
65
|
87
|
112
|
147
|
232
|
225
|
|
| Accrued Liabilities |
38
|
50
|
46
|
46
|
41
|
50
|
46
|
75
|
92
|
103
|
|
| Short-Term Debt |
89
|
48
|
88
|
111
|
46
|
76
|
150
|
390
|
589
|
611
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
93
|
40
|
|
| Other Current Liabilities |
48
|
58
|
35
|
29
|
32
|
60
|
64
|
33
|
82
|
54
|
|
| Total Current Liabilities |
221
|
202
|
227
|
253
|
184
|
273
|
372
|
645
|
1 088
|
1 031
|
|
| Long-Term Debt |
15
|
0
|
0
|
0
|
0
|
0
|
99
|
149
|
62
|
14
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
1
|
1
|
3
|
3
|
3
|
1
|
|
| Minority Interest |
35
|
42
|
48
|
62
|
70
|
81
|
81
|
89
|
117
|
132
|
|
| Other Liabilities |
67
|
68
|
65
|
61
|
64
|
62
|
62
|
48
|
55
|
64
|
|
| Total Liabilities |
338
N/A
|
311
-8%
|
339
+9%
|
376
+11%
|
319
-15%
|
417
+31%
|
617
+48%
|
934
+51%
|
1 326
+42%
|
1 243
-6%
|
|
| Equity | |||||||||||
| Common Stock |
116
|
116
|
116
|
116
|
155
|
155
|
252
|
252
|
253
|
253
|
|
| Retained Earnings |
368
|
400
|
428
|
453
|
500
|
578
|
675
|
704
|
760
|
797
|
|
| Additional Paid In Capital |
1
|
1
|
1
|
1
|
309
|
308
|
694
|
705
|
712
|
703
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
17
|
16
|
15
|
|
| Other Equity |
0
|
0
|
0
|
0
|
2
|
7
|
16
|
0
|
0
|
0
|
|
| Total Equity |
484
N/A
|
517
+7%
|
544
+5%
|
570
+5%
|
962
+69%
|
1 034
+7%
|
1 605
+55%
|
1 645
+3%
|
1 708
+4%
|
1 738
+2%
|
|
| Total Liabilities & Equity |
822
N/A
|
828
+1%
|
884
+7%
|
945
+7%
|
1 281
+36%
|
1 452
+13%
|
2 222
+53%
|
2 579
+16%
|
3 034
+18%
|
2 981
-2%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
162
|
162
|
162
|
162
|
217
|
217
|
252
|
252
|
253
|
253
|
|